pentobarbital will reduce the level or effect of diazepam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong or moderate CYP3A4 inducers may well maximize amount of diazepam elimination; hence, efficacy of diazepam can be lowered.
pentobarbital will decrease the level or influence of buprenorphine subdermal implant by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Observe Intently. Monitor patients currently on buprenorphine subdermal implant who need freshly-initiated therapy with CYP3A4 inducer for indicators and indications of withdrawal.
Comment: Barbiturates may well raise adverse effects, which include respiratory despair, produced by harmful doses of TCAs. With therapeutic doses of TCAs, barbiturates maximize metabolism and reduce blood concentrations of TCAs.
Warning when discontinuing CYP3A4 inducers which might be coadministered with benzhydrocodone (prodrug of hydrocodone); plasma concentrations of hydrocodone may perhaps raise and may end up in probably lethal respiratory despair.
Remark: Barbiturates may boost adverse effects, like respiratory despair, produced by poisonous doses of TCAs. With therapeutic doses of TCAs, barbiturates increase metabolism and reduce blood concentrations of TCAs.
pentobarbital increases toxicity of ifosfamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Watch. CYP3A4 inducers may well improve the metabolism of ifosfamide to its Energetic alkylating metabolites.
pentobarbital will lessen the level or outcome of estropipate by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Observe.
pentobarbital will lower the extent or result of ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Solid CYP3A4 inducers may possibly decrease partiaprevir and ritonavir ranges, and as a consequence lowered efficacy of Viekira Pak
pentobarbital will minimize the level or outcome of budesonide by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Monitor.
pentobarbital will lower the level or outcome of doravirine by influencing hepatic/intestinal enzyme CYP3A4 metabolism.
pentobarbital will lower the extent or result of terbinafine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Warning/Keep track of.
Drugs that need prior authorization. This restriction necessitates that certain scientific conditions be satisfied ahead of the approval on the prescription.
pentobarbital will lower the level or outcome of diazepam by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.
pentobarbital will here lower the extent or effect of tofacitinib by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Keep an eye on. Loss of, or diminished response to tofacitinib may possibly happen when coadministered with powerful CYP3A4 inducers